Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Friday, June 14, 2024 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Class Action

BOSTON - Directors inflated the price of Ariad Pharmaceuticals stock by failing to disclose side effects of its cancer drug Iclusig (ponatinib), and the share price dropped by 66 percent when the truth came out, shareholders claim in Federal Court.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...